Phase 1 Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment.

Mark J Roschewski Manish R Patel Patrick M Reagan Nakhle S Saba Graham P Collins Hendrick-Tobias Arkenau Sven de Vos Barret R B Nuttall Melih Acar Kathleen Burke Rafael D White Maria Udriste Shringi Sharma Brian Dougherty Daniel Stetson David F Jenkins Andrew Mortlock Alessandra Forcina Veerendra Munugalavadla Ian W Flinn

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Targeting both STAT3 and BTK in combination is safe and tolerable but efficacy is limited in R/R DLBCL. Results support evaluation of circulating tumor DNA as a biomarker for clinical response.

Keyphrases

circulating tumor
diffuse large b cell lymphoma
cell free
epstein barr virus
circulating tumor cells
tyrosine kinase
cell proliferation
cancer therapy
randomized controlled trial
acute myeloid leukemia
drug delivery
double blind